Advertisement

Patient prioritisation in HCC treatment: All (good) things come in threes

Published:February 26, 2018DOI:https://doi.org/10.1016/j.jhep.2017.11.035
      Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and a major cause of mortality amongst patients with liver cirrhosis.
      • Torre L.A.
      • Bray F.
      • Siegel R.L.
      • Ferlay J.
      • Lortet-Tieulent J.
      • Jemal A.
      Global cancer statistics, 2012.
      Despite progress in surveillance programmes, only about 30% of patients in Western countries are eligible for potentially curative treatment approaches, such as surgical resection, orthotopic liver transplantation (LT) or local ablation because of extensive tumour burden and/or impaired liver function.
      • Bruix J.
      • Reig M.
      • Sherman M.
      Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma.
      Consistently, all treatment decisions in each individual patient should be based on a multidisciplinary team (MDT) discussion best guided by an established classification system to optimise the patient’s outcome.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      Authors names in bold designate shared co-first authorship

        • Torre L.A.
        • Bray F.
        • Siegel R.L.
        • Ferlay J.
        • Lortet-Tieulent J.
        • Jemal A.
        Global cancer statistics, 2012.
        CA Cancer J Clin. 2015; 65: 87-108
        • Bruix J.
        • Reig M.
        • Sherman M.
        Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma.
        Gastroenterology. 2016; 150: 835-853
        • European Association for Study of Liver
        • European Organisation for Research and Treatment of Cancer
        EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.
        J Hepatol. 2012; 56: 908-943
        • Galle P.R.
        • Tovoli F.
        • Foerster F.
        • Worns M.A.
        • Cucchetti A.
        • Bolondi L.
        The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy.
        J Hepatol. 2017; 67: 173-183
        • Llovet J.M.
        • Ricci S.
        • Mazzaferro V.
        • Hilgard P.
        • Gane E.
        • Blanc J.F.
        • et al.
        Sorafenib in advanced hepatocellular carcinoma.
        N Engl J Med. 2008; 359: 378-390
        • Bruix J.
        • Qin S.
        • Merle P.
        • Granito A.
        • Huang Y.H.
        • Bodoky G.
        • et al.
        Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
        Lancet. 2017; 389: 56-66
        • El-Khoueiry A.B.
        • Sangro B.
        • Yau T.
        • Crocenzi T.S.
        • Kudo M.
        • Hsu C.
        • et al.
        Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
        Lancet. 2017; 389: 2492-2502
        • Adhoute X.
        • Penaranda G.
        • Raoul J.L.
        • Le Treut P.
        • Bollon E.
        • Hardwigsen J.
        • et al.
        Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments.
        World J Hepatol. 2016; 8: 703-715
        • Song P.
        • Cai Y.
        • Tang H.
        • Li C.
        • Huang J.
        The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines from 2001 to 2017.
        Biosci Trends. 2017; 11: 389-398
        • Heimbach J.
        • Kulik L.M.
        • Finn R.
        • Sirlin C.B.
        • Abecassis M.
        • Roberts L.R.
        • et al.
        Aasld guidelines for the treatment of hepatocellular carcinoma.
        Hepatology. 2018; 67: 358-380